A206640 Stock Overview
Boditech Med Inc. offers instruments and diagnostic reagents in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Boditech Med Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩14,840.00 |
| 52 Week High | ₩22,150.00 |
| 52 Week Low | ₩11,230.00 |
| Beta | -0.53 |
| 1 Month Change | 3.78% |
| 3 Month Change | -18.46% |
| 1 Year Change | 22.44% |
| 3 Year Change | -41.57% |
| 5 Year Change | 35.53% |
| Change since IPO | -73.33% |
Recent News & Updates
Recent updates
Boditech Med Inc. (KOSDAQ:206640) Shares Fly 49% But Investors Aren't Buying For Growth
Apr 16
Here's Why I Think Boditech Med (KOSDAQ:206640) Might Deserve Your Attention Today
Apr 13Could The Market Be Wrong About Boditech Med Inc. (KOSDAQ:206640) Given Its Attractive Financial Prospects?
Mar 01Boditech Med (KOSDAQ:206640) Seems To Use Debt Rather Sparingly
Jan 18
Here's Why I Think Boditech Med (KOSDAQ:206640) Is An Interesting Stock
Dec 28Did Business Growth Power Boditech Med's (KOSDAQ:206640) Share Price Gain of 193%?
Dec 08Boditech Med Inc. (KOSDAQ:206640) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 18Shareholder Returns
| A206640 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | -1.3% | 3.0% | -3.3% |
| 1Y | 22.4% | 26.1% | 1.2% |
Return vs Industry: A206640 underperformed the KR Medical Equipment industry which returned 26.1% over the past year.
Return vs Market: A206640 exceeded the KR Market which returned 1.2% over the past year.
Price Volatility
| A206640 volatility | |
|---|---|
| A206640 Average Weekly Movement | 6.7% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A206640's share price has been volatile over the past 3 months.
Volatility Over Time: A206640's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 457 | n/a | www.boditech.co.kr/en |
Boditech Med Inc. offers instruments and diagnostic reagents in South Korea and internationally. The company offers instruments, including ichroma II, diagnostic immuno-analyzer to measure the presence of various biomarkers for cardiac, cancer, hormones, infectious diseases, autoimmune diseases, and metabolic diseases; ichroma III, a high-throughput immuno-analyzer that enables simultaneous testing for various parameters; ExAmplar, a compact real time PCR that detects virus/bacteria quantitatively or qualitatively using ready-to-use cartridges; ichroma-50, an automated immunoassay system with high-throughput; Hemochroma PLUS, a handheld device that can run tests for anemia; portable analyzers ichroma M3 and ichroma M2; and NuActor, an automated nucleic acid extraction system. It also provides compact immunoassay analyzers, including AFIAS-1, AFIAS-3, AFIAS-6, and AFIAS-10; cardiac reagents; cancer reagents; COVID-19 reagents; diagnostic reagents; reagents for hormones, infections, autoimmune, organ functions, molecular diagnostics, therapeutic drug monitoring, and other test items.
Boditech Med Inc. Fundamentals Summary
| A206640 fundamental statistics | |
|---|---|
| Market cap | ₩326.02b |
| Earnings (TTM) | ₩25.95b |
| Revenue (TTM) | ₩134.22b |
12.6x
P/E Ratio2.4x
P/S RatioIs A206640 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A206640 income statement (TTM) | |
|---|---|
| Revenue | ₩134.22b |
| Cost of Revenue | ₩53.72b |
| Gross Profit | ₩80.50b |
| Other Expenses | ₩54.55b |
| Earnings | ₩25.95b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.18k |
| Gross Margin | 59.97% |
| Net Profit Margin | 19.33% |
| Debt/Equity Ratio | 4.7% |
How did A206640 perform over the long term?
See historical performance and comparison